CSIMarket Company Name, Ticker, Industry, else..
 
Nautilus Biotechnology Inc   (NASDAQ: NAUT)
Other Ticker:  
 
 
Price: $0.7701 $-0.01 -1.534%
Day's High: $0.83 Week Perf: -4.93 %
Day's Low: $ 0.75 30 Day Perf: -31.24 %
Volume (M): 69 52 Wk High: $ 3.09
Volume (M$): $ 53 52 Wk Avg: $2.19
Open: $0.77 52 Wk Low: $0.66



 Market Capitalization (Millions $) 97
 Shares Outstanding (Millions) 126
 Employees 72
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -71
 Cash Flow (TTM) (Millions $) 8
 Capital Exp. (TTM) (Millions $) 2

Nautilus Biotechnology Inc
Nautilus Biotechnology Inc. is a life sciences company based in California, United States. The company focuses on developing and commercializing novel tools and technologies for the analysis of proteins and their functions. Their aim is to advance the understanding of human biology and enable more effective drug discovery and development.

Nautilus Biotechnology has developed a high-throughput, single-molecule protein analysis platform called the Nautilus Proteomic Discovery Platform. This platform combines imaging, protein tagging, and sequencing technologies to enable the study of proteins at an unprecedented level of detail. It has the potential to revolutionize the field of proteomics by providing comprehensive insights into protein structure, function, and interactions.

By providing a comprehensive view of the proteome, Nautilus Biotechnology's technology can help uncover new therapeutic targets, identify disease mechanisms, and accelerate the development of precision medicines. The company collaborates with academic institutions, biotech companies, and pharmaceutical companies to apply their platform in various areas of research and drug discovery.

Nautilus Biotechnology was founded in 2016 by a team of experienced scientists and entrepreneurs. Since its inception, the company has raised significant funding from investors and has attracted renowned scientific and business advisors. With its innovative technology and focus on protein analysis, Nautilus Biotechnology aims to make significant contributions to the field of life sciences.


   Company Address: 2701 Eastlake Avenue East Seattle 98102 WA
   Company Phone Number: 333-2001   Stock Exchange / Ticker: NASDAQ NAUT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
A   -0.22%    
BIO   -1.68%    
ILMN   -2.24%    
MTD   -3.55%    
RVTY   -3.2%    
TXG        4.68% 
• View Complete Report
   



Nautilus Biotechnology Inc

Nautilus Biotechnology Inc Reports Operating Loss of $-21.607 Million in Q1 2024 Financial Results

Nautilus Biotechnology Inc: A Closer Look at Q1 2024 Financial Results
As an avid investor, I have closely followed Nautilus Biotechnology Inc's financial performance over the past few months. The recently released financial results for the first quarter ended March 31, 2024, provide some interesting insights into the company's operations and profitability.
One of the key highlights from the financial report is the operating loss incurred by Nautilus during the period. The company reported an operating loss of $-21.607 million, highlighting the challenges faced by the business. It is worth mentioning that this operating loss has increased from $-18.06 million incurred during the first quarter of 2023.
Nautilus Biotechnology Inc

Nautilus Biotechnology Inc. Faces Growing Operating Deficit 2.

Nautilus Biotechnology Inc is a company operating in the Laboratory Analytical Instruments sector. The company recently reported an operating deficit of $-20.001 million for the most recent fiscal period, which is an increase from the previous quarter's deficit of $-16.304 million. This has raised concerns among market observers about when the company will start reporting revenue.
Like many businesses, Nautilus Biotechnology Inc is going through a challenging period as it seeks to establish a lucrative business model. The net loss for the most recent fiscal period has widened to $-17.024 million. In the financial year 2023, the company announced a loss of $-63.68 million and revenue of $0.00 million. The net loss per share has also increased to $-0.51 from $-0.46 in the prior financial year.
Nautilus Biotechnology Inc

Nautilus Biotechnology's Financial Woes: Operating Shortfall of $-19.075 Million Sparks Concerns

Nautilus Biotechnology Inc, a company operating in the Laboratory Analytical Instruments sector, has recently disclosed its financial numbers for the July to September 30, 2023 reporting cycle. Unfortunately for the shareholders, the company announced an operating shortfall of $-19.075 million for the most recent fiscal period. This is certainly not good news and raises concerns about the firm's financial performance.
Looking ahead to the approaching cycle, shareholders are eagerly anticipating additional business strategy to be implemented as soon as possible. The markets, however, seem less concerned about the current execution of the organization. The CEO of Nautilus Biotechnology Inc is on the lookout for distinct business strategies in order to ensure consistent service. The hope is that these strategies will help improve the company's financial situation and bring it back on track.
Nautilus Biotechnology Inc

Nautilus Biotechnology Inc. Reports Operating Loss of $-19.016 Million in Second Fiscal Quarter of 2023 Amidst Declining Performance

Nautilus Biotechnology Inc, a company in the Laboratory Analytical Instruments sector, recently reported its financial results for the second quarter of 2023. The company's operating loss expanded to $-19.016 million, compared to $-15.472 million in the same period last year. Additionally, Nautilus Biotechnology Inc reported a net loss of $-15.808 million, which also increased from $-14.689 million in the previous year.
These financial results raise speculation among market observers about the company's future performance. The focus now shifts to whether Nautilus Biotechnology Inc will be able to improve its top-line results. The upcoming financial report scheduled for October 31, 2023, is highly anticipated as investors and analysts closely watch for any indications of positive growth in the company's revenue.
Nautilus Biotechnology Inc

Nautilus Biotechnology Inc , deterioration in the operating results all over first quarter of 2023 earnings season

Investors who follow the stock market closely are always on the lookout for companies with high potential. Nautilus Biotechnology Inc, a company in the healthcare sector, may not have had the best financial results in the past year, but there are reasons to be optimistic about its future.
During the 12 months ending in the first quarter of 2023, Nautilus Biotechnology Inc experienced a cumulative net loss of $-57 million, which translated to a negative return on investment (ROI) of -16.33%. Despite this setback, the overall ROI ranking for the company has improved significantly from 3537 in the fourth quarter of 2022 to 600 as of March 31, 2023.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com